[1]
|
(2014) The Global Asthma Report 2014. Global Asthma Network, Auckland.
http://www.globalasthmareport.org|resources|Global_Asthma_Report_2014
|
[2]
|
林江涛. 抗IgE治疗过敏性哮喘的长期有效性和安全性[J]. 中华结核和呼吸杂志, 2016, 39(9): 733-736.
|
[3]
|
Schatz, M. and Rosenwasser, L. (2014) The Allergic Asthma Phenotype. The Journal of Allergy and Clinical Immunology: In Practice, 2, 645-649. ://doi.org/10.1016/j.jaip.2014.09.004
|
[4]
|
Pelaia, C., Calabrese, C., Terracciano, R., de Blasio, F., Vatrella, A. and Pelaia, G. (2018) Omalizumab, the First Available Antibody for Biological Treatment of Severe Asthma: More than a Decade of Real-Life Effectiveness. Therapeutic Advances in Respiratory Disease, 12, 1753466618810192. ://doi.org/10.1177/1753466618810192
|
[5]
|
Ribatti, D. (2016) The Discovery of Immunoglobulin E. Immunology Letters, 171, 1-4.
://doi.org/10.1016/j.imlet.2016.01.001
|
[6]
|
Mitropoulou, A.N., Ceska, T., Heads, J.T., et al. (2020) Engineering the Fab Fragment of the Anti-IgE Omalizumab to Prevent Fab Crystallization and Permit IgE-Fc Complex Crystallization. Acta Crystallographica Section F: Structural Biology Communications, 76, 116-129. ://doi.org/10.1107/S2053230X20001466
|
[7]
|
Rath, N., Raje, N. and Rosenwasser, L. (2018) Immunoglobulin E as a Biomarker in Asthma. Immunology and Allergy Clinics of North America, 38, 587-597. ://doi.org/10.1016/j.iac.2018.06.007
|
[8]
|
Navinés-Ferrer, A., Serrano-Candelas, E., Molina-Molina, G.J. and Martín, M. (2016) IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. Journal of Immunology Research, 2016, Article ID: 8163803.
://doi.org/10.1155/2016/8163803
|
[9]
|
Anto, J.M., Bousquet, J., Akdis, M., et al. (2017) Mechanisms of the Development of Allergy (MeDALL): Introducing Novel Concepts in Allergy Phenotypes. The Journal of Allergy and Clinical Immunology, 139, 388-399.
://doi.org/10.1016/j.jaci.2016.12.940
|
[10]
|
Galli, S.J. and Tsai, M. (2012) IgE and Mast Cells in Allergic Disease. Nature Medicine, 18, 693-704.
://doi.org/10.1038/nm.2755
|
[11]
|
Humbert, M., Bousquet, J., Bachert, C., et al. (2019) IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. The Journal of Allergy and Clinical Immunology: In Practice, 7, 1418-1429.
://doi.org/10.1016/j.jaip.2019.02.030
|
[12]
|
(2002) Omalizumab: Anti-IgE Monoclonal Antibody E25, E25, Humanised Anti-IgE MAb, IGE 025, Monoclonal Antibody E25, Olizumab, Xolair, rhuMAb-E25. BioDrugs, 16, 380-386.
://doi.org/10.2165/00063030-200216050-00009
|
[13]
|
Presta, L.G., Lahr, S.J., Shields, R.L., et al. (1993) Humanization of an Antibody Directed against IgE. Journal of Immunology, 151, 2623-2632.
|
[14]
|
Pelaia, G., Gallelli, L., Renda, T., et al. (2011) Update on Optimal Use of Omalizumab in Management of Asthma. Journal of Asthma and Allergy, 4, 49-59. ://doi.org/10.2147/JAA.S14520
|
[15]
|
Chang, T.W., Wu, P.C., Hsu, C.L. and Hung, A.F. (2007) Anti-IgE Antibodies for the Treatment of IgE-Mediated Allergic Diseases. Advances in Immunology, 93, 63-119. ://doi.org/10.1016/S0065-2776(06)93002-8
|
[16]
|
Hochhaus, G., Brookman, L., Fox, H., et al. (2003) Pharmacodynamics of Omalizumab: Implications for Optimised Dosing Strategies and Clinical Efficacy in the Treatment of Allergic Asthma. Current Medical Research and Opinion, 19, 491-498. ://doi.org/10.1185/030079903125002171
|
[17]
|
Fox, J.A., Hotaling, T.E., Struble, C., Ruppel, J., Bates, D.J. and Schoenhoff, M.B. (1996) Tissue Distribution and Complex Formation with IgE of an Anti-IgE Antibody after Intravenous Administration in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 279, 1000-1008.
|
[18]
|
Hoshino, M. and Ohtawa, J. (2012) Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma. Respiration, 83, 520-528. ://doi.org/10.1159/000334701
|
[19]
|
Wright, J.D., Chu, H.M., Huang, C.H., Ma, C., Chang, T.W. and Lim, C. (2015) Structural and Physical Basis for Anti-IgE Therapy. Scientific Reports, 5, Article No. 11581. ://doi.org/10.1038/srep11581
|
[20]
|
Hendeles, L. and Sorkness, C.A. (2007) Anti-Immunoglobulin E Therapy with Omalizumab for Asthma. Annals of Pharmacotherapy, 41, 1397-1410. ://doi.org/10.1345/aph.1K005
|
[21]
|
European Medicines Agency (2016) Xolair-Product Information.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf
|
[22]
|
Marcus, P., Practice Management Committee, American College of Chest Physicians (2006) Incorporating Anti-IgE (Omalizumab) Therapy into Pulmonary Medicine Practice: Practice Management Implications. Chest, 129, 466-474.
://doi.org/10.1378/chest.129.2.466
|
[23]
|
Miller, C.W., Krishnaswamy, N., Johnston, C. and Krishnaswamy, G. (2008) Severe Asthma and the Omalizumab Option. Clinical and Molecular Allergy, 6, 4. ://doi.org/10.1186/1476-7961-6-4
|
[24]
|
Luu, M., Bardou, M., Bonniaud, P. and Goirand, F. (2016) Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Omalizumab for the Treatment of Asthma. Expert Opinion on Drug Metabolism & Toxicology, 12, 1503-1511.
://doi.org/10.1080/17425255.2016.1248403
|
[25]
|
李靖. 奥马珠单抗治疗过敏性哮喘的中国专家共识[J]. 中华结核和呼吸杂志, 2018, 41(3): 179-185.
|
[26]
|
Vignola, A.M., Humbert, M., Bousquet, J., et al. (2004) Efficacy and Tolerability of Anti-Immunoglobulin E Therapy with Omalizumab in Patients with Concomitant Allergic Asthma and Persistent Allergic Rhinitis: SOLAR. Allergy, 59, 709-717. ://doi.org/10.1111/j.1398-9995.2004.00550.x
|
[27]
|
Humbert, M., Beasley, R., Ayres, J., et al. (2005) Benefits of Omalizumab as Add-On Therapy in Patients with Severe Persistent Asthma Who Are Inadequately Controlled Despite Best Available Therapy (GINA 2002 Step 4 Treatment): INNOVATE. Allergy, 60, 309-316. ://doi.org/10.1111/j.1398-9995.2004.00772.x
|
[28]
|
Martínez-Moragón, E., Climent, M., Chiner, E., Fernández-Aracil, C., Sánchez-Toril, F. and Lluch-Tortajada, I. (2019) Effectiveness and Pharmacoeconomic Analysis of the Treatment of Severe Asthma with Omalizumab in Clinical Practice. Efectividad y análisis farmacoeconómico del tratamiento del asma grave con omalizumab en la práctica clínica. Farmacia Hospitalaria, 43, 101-109.
|
[29]
|
Adachi, M., Kozawa, M., Yoshisue, H., et al. (2018) Real-World Safety and Efficacy of Omalizumab in Patients with Severe Allergic Asthma: A Long-Term Post-Marketing Study in Japan. Respiratory Medicine, 141, 56-63.
://doi.org/10.1016/j.rmed.2018.06.021
|
[30]
|
Al-Ahmad, M., Arifhodzic, N., Nurkic, J., et al. (2018) “Real-Life” Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma. Medical Principles and Practice, 27, 260-266. ://doi.org/10.1159/000487482
|
[31]
|
Frix, A.N., Schleich, F., Paulus, V., Guissard, F., Henket, M. and Louis, R. (2020) Effectiveness of Omalizumab on Patient Reported Outcomes, Lung Function, and Inflammatory Markers in Severe Allergic Asthma. Biochemical Pharmacology, 179, Article ID: 113944. ://doi.org/10.1016/j.bcp.2020.113944
|
[32]
|
Pelaia, C., Calabrese, C., Barbuto, S., et al. (2019) Omalizumab Lowers Asthma Exacerbations, Oral Corticosteroid Intake and Blood Eosinophils: Results of a 5-YEAR Single-Centre Observational Study. Pulmonary Pharmacology & Therapeutics, 54, 25-30. ://doi.org/10.1016/j.pupt.2018.11.002
|
[33]
|
Busse, W.W., Morgan, W.J., Gergen, P.J., et al. (2011) Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. The New England Journal of Medicine, 364, 1005-1015. ://doi.org/10.1056/NEJMoa1009705
|
[34]
|
Busse, W.W., Humbert, M., Haselkorn, T., et al. (2020) Effect of Omalizumab on Lung Function and Eosinophil Levels in Adolescents with Moderate-to-Severe Allergic Asthma. Annals of Allergy, Asthma & Immunology, 124, 190-196. ://doi.org/10.1016/j.anai.2019.11.016
|
[35]
|
Gibson, P.G., Reddel, H., McDonald, V.M., et al. (2016) Effectiveness and Response Predictors of Omalizumab in a Severe Allergic Asthma Population with a High Prevalence of Comorbidities: The Australian Xolair Registry. Internal Medicine Journal, 46, 1054-1062. ://doi.org/10.1111/imj.13166
|
[36]
|
Ledford, D., Busse, W., Trzaskoma, B., et al. (2017) A Randomized Multicenter Study Evaluating Xolair Persistence of Response after Long-Term Therapy. The Journal of Allergy and Clinical Immunology, 140, 162-169.e2.
://doi.org/10.1016/j.jaci.2016.08.054
|
[37]
|
Nopp, A., Johansson, S.G., Adédoyin, J., Ankerst, J., Palmqvist, M. and Oman, H. (2010) After 6 Years with Xolair; a 3-Year Withdrawal Follow-Up. Allergy, 65, 56-60. ://doi.org/10.1111/j.1398-9995.2009.02144.x
|
[38]
|
Kupryś-Lipińska, I. and Kuna, P. (2014) Loss of Asthma Control after Cessation of Omalizumab Treatment: Real Life Data. Postępy Dermatologii i Alergologii, 31, 1-5. ://doi.org/10.5114/pdia.2014.40553
|
[39]
|
Cox, L., Platts-Mills, T.A., Finegold, I., et al. (2007) American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on Omalizumab-Associated Anaphylaxis. The Journal of Allergy and Clinical Immunology, 120, 1373-1377. ://doi.org/10.1016/j.jaci.2007.09.032
|
[40]
|
Di Bona, D., Fiorino, I., Taurino, M., et al. (2017) Long-Term “Real-Life” Safety of Omalizumab in Patients with Severe Uncontrolled Asthma: A Nine-Year Study. Respiratory Medicine, 130, 55-60.
://doi.org/10.1016/j.rmed.2017.07.013
|
[41]
|
Schreiber, J., Schwab Sauerbeck, I. and Mailänder, C. (2020) The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study. Advances in Therapy, 37, 353-363. ://doi.org/10.1007/s12325-019-01135-w
|
[42]
|
Rodrigo, G.J., Neffen, H. and Castro-Rodriguez, J.A. (2011) Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-On Therapy to Corticosteroids for Children and Adults with Asthma: A Systematic Review. Chest, 139, 28-35. ://doi.org/10.1378/chest.10-1194
|
[43]
|
Iribarren, C., Rahmaoui, A., Long, A.A., et al. (2017) Cardiovascular and Cerebrovascular Events among Patients Receiving Omalizumab: Results from EXCELS, a Prospective Cohort Study in Moderate to Severe Asthma. The Journal of Allergy and Clinical Immunology, 139, 1489-1495.e5. ://doi.org/10.1016/j.jaci.2016.07.038
|
[44]
|
Long, A., Rahmaoui, A., Rothman, K.J., et al. (2014) Incidence of Malignancy in Patients with Moderate-to-Severe Asthma Treated with or without Omalizumab. The Journal of Allergy and Clinical Immunology, 134, 560-567.e4.
://doi.org/10.1016/j.jaci.2014.02.007
|
[45]
|
Cruz, A.A., Lima, F., Sarinho, E., et al. (2007) Safety of Anti-Immunoglobulin E Therapy with Omalizumab in Allergic Patients at Risk of Geohelminth Infection. Clinical & Experimental Allergy, 37, 197-207.
://doi.org/10.1111/j.1365-2222.2007.02650.x
|